We are live on ! Find out more
CYCN icon

Cyclerion Therapeutics
CYCN

67 hedge funds and large institutions have $96M invested in Cyclerion Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more call options, than puts

Call options by funds: $2.07M | Put options by funds: $779K

54% more capital invested

Capital invested by funds: $62.4M → $96M (+$33.6M)

0.24% less ownership

Funds ownership: 3.29% → 3.05% (-0.24%)

4% less funds holding

Funds holding: 70 → 67 (-3)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

Holders
67
Holders Change
-3
Holders Change %
-4.29%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
15
Reduced
20
Closed
20
Calls
$2.07M
Puts
$779K
Net Calls
+$1.29M
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$3.01M
2
MP
MFN Partners
Massachusetts
+$3.01M
3
SPC
Slate Path Capital
New York
+$3.01M
4
PVI
Pura Vida Investments
New York
+$1.59M
5
Millennium Management
Millennium Management
New York
+$1.22M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.91M
2
State Street
State Street
Massachusetts
-$992K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$769K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$553K
5
Northern Trust
Northern Trust
Illinois
-$546K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$27.9M +$3.01M +48,077 +16%
MP
2
MFN Partners
Massachusetts
$13.2M +$3.01M +48,077 +40%
AG
3
Artal Group
Luxembourg
$10.8M +$3.01M +48,077 +53%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$10.4M -$161K -2,575 -2%
EC
5
EcoR1 Capital
California
$6.26M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$5.55M -$769K -12,280 -15%
IC
7
Ikarian Capital
Texas
$1.99M +$657K +10,496 +70%
PVI
8
Pura Vida Investments
New York
$1.98M +$1.59M +25,374 New
BlackRock
9
BlackRock
New York
$1.7M -$3.91M -62,467 -74%
Millennium Management
10
Millennium Management
New York
$1.52M +$1.22M +19,452 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.5M -$320K -5,107 -21%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$1.46M +$960K +15,339 +448%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$1.27M +$491K +7,835 +92%
Renaissance Technologies
14
Renaissance Technologies
New York
$1.11M +$161K +2,577 +22%
TFS
15
TrustCore Financial Services
Tennessee
$773K – – –
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$620K +$306K +4,893 +160%
Two Sigma Investments
17
Two Sigma Investments
New York
$599K -$10.1K -161 -2%
Charles Schwab
18
Charles Schwab
California
$506K -$219K -3,503 -35%
QI
19
QS Investors
New York
$453K – – –
SFI
20
Susquehanna Fundamental Investments
Pennsylvania
$412K +$331K +5,279 New
CG
21
Colony Group
Massachusetts
$401K – – –
E
22
Ergoteles
New York
$375K +$301K +4,805 New
Citadel Advisors
23
Citadel Advisors
Florida
$352K +$238K +3,804 +535%
TEE
24
Tibra Equities Europe
United Kingdom
$332K +$266K +4,250 New
State Street
25
State Street
Massachusetts
$325K -$992K -15,841 -79%
1
2 3 4

CYCN Hedge Fund Activity: Q2 2021 in Review

67 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2021, worth a combined $96M — up 54% from $62.4M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CYCN and 17 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 15 added.

The largest buyer was Artal Group, adding an estimated $3.01M. The largest seller was BlackRock, cutting an estimated $3.91M.

  • 67 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2021, down from 70 in Q1 2021.
  • Funds reported $96M of Cyclerion Therapeutics stock for Q2 2021, up 54% quarter-over-quarter.
  • 17 funds opened new Cyclerion Therapeutics positions in Q2 2021 and 20 closed out, a net change of -3 holders.
  • The largest Cyclerion Therapeutics buyer in Q2 2021 was Artal Group, an estimated $3.01M added.
  • The largest Cyclerion Therapeutics seller in Q2 2021 was BlackRock, an estimated $3.91M sold.

Based on aggregated 13F filings for Q2 2021.